{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:15Z","timestamp":1790743335401,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Department of Orthopedic Surgery at Mayo Clinic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Owing to patient intolerance or drug interactions, alternative agents to rifampin are needed for management of staphylococcal periprosthetic joint infection. In the current study, we evaluated rifabutin, rifapentine and rifampin, with and without vancomycin, in a rat model of foreign body osteomyelitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Proximal tibiae were inoculated with methicillin-resistant Staphylococcus aureus (MRSA) and a Kirschner wire (K-wire) implanted in each. After 4 weeks of infection, rifampin, rifabutin, or rifapentine were administered, alone or with vancomycin. Tibiae and K-wires were cultured, and medians were reported as log10 colony-forming units (CFUs) per gram of bone or log10 CFUs per K-wire, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Rifampin, rifabutin or rifapentine administered with vancomycin yielded less MRSA from bones (0.10, 3.02, and 0.10 log10 CFUs\/g, respectively) than did no treatment (4.36 log10 CFUs\/g) or vancomycin alone (4.64 log10 CFUs\/g) (both P\u2005\u2264\u2005.02). The K-wires of animals receiving no treatment or vancomycin monotherapy recovered medians of 1.76 and 2.91 log10 CFUs\/g per K-wire, respectively. In contrast, rifampin, rifabutin and rifapentine administered with vancomycin yielded medians of 0.1 log10 CFUs per K-wire, respectively. Rifampin resistance was detected in a single animal in the rifampin monotherapy group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Rifabutin or rifapentine with vancomycin were as active as rifampin with vancomycin against MRSA in rat foreign body osteomyelitis, suggesting that rifabutin and\/or rifapentine may be alternatives to rifampin in the clinical management of staphylococcal periprosthetic joint infections.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa401","type":"journal-article","created":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T19:06:47Z","timestamp":1593976007000},"page":"1498-1504","source":"Crossref","is-referenced-by-count":25,"title":["Novel Use of Rifabutin and Rifapentine to Treat Methicillin-Resistant Staphylococcus aureus in a Rat Model of Foreign Body Osteomyelitis"],"prefix":"10.1093","volume":"222","author":[{"given":"Melissa J","family":"Karau","sequence":"first","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzannah M","family":"Schmidt-Malan","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Albano","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayawant N","family":"Mandrekar","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina G","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R","family":"Osmon","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Rochester, Minnesota, USA"},{"name":"Department of Orthopaedic Surgery, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin P","family":"Oravec","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P","family":"Abdel","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA"},{"name":"Department of Pharmacy, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"2020110419212974700_CIT0001","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2020110419212974700_CIT0002","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/CMR.00111-13","article-title":"Prosthetic joint infection","volume":"27","author":"Tande","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2020110419212974700_CIT0003","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020110419212974700_CIT0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1302\/0301-620X.101B7.BJJ-2018-1189.R1","article-title":"Prior hip or knee prosthetic joint infection in another joint increases risk three-fold of prosthetic joint infection after primary total knee arthroplasty: a matched control study","volume":"101-B","author":"Chalmers","year":"2019","journal-title":"Bone Joint J"},{"key":"2020110419212974700_CIT0005","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2106\/JBJS.18.01218","article-title":"Long-term survivorship of total hip arthroplasty with highly cross-linked polyethylene for osteonecrosis","volume":"101","author":"Hart","year":"2019","journal-title":"J Bone Joint Surg Am"},{"key":"2020110419212974700_CIT0006","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1302\/0301-620X.100B11.BJJ-2018-0515.R1","article-title":"Irrigation and debridement with chronic antibiotic suppression for the management of infected total knee arthroplasty: a contemporary analysis","volume":"100","author":"Weston","year":"2018","journal-title":"Bone Joint J"},{"key":"2020110419212974700_CIT0007","doi-asserted-by":"crossref","first-page":"e00959-19","DOI":"10.1128\/AAC.00959-19","article-title":"In vitro activity of rifampin, rifabutin, rifapentine and rifaximin against planktonic and biofilm sates of staphylococci isolated from periprosthetic joint infection","volume":"63","author":"Albano","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419212974700_CIT0008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2016.01.008","article-title":"In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections","volume":"85","author":"Schmidt-Malan","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020110419212974700_CIT0009","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1128\/AAC.46.3.900-903.2002","article-title":"Penetration of rifampin through Staphylococcus epidermidis biofilms","volume":"46","author":"Zheng","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419212974700_CIT0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/AAC.50.1.55-61.2006","article-title":"Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections","volume":"50","author":"Saginur","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419212974700_CIT0011","doi-asserted-by":"crossref","first-page":"e01746-18","DOI":"10.1128\/AAC.01746-18","article-title":"Role of rifampin against staphylococcal biofilm infections in vitro, in animal models, and in orthopedic-device-related infections","volume":"63","author":"Zimmerli","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419212974700_CIT0012","first-page":"73","article-title":"Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin","volume":"82","author":"Henry","year":"1987","journal-title":"Am J Med"},{"key":"2020110419212974700_CIT0013","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1128\/AAC.23.2.338","article-title":"Comparison of concentrations of rifampin and a new rifamycin derivative, DL 473, in canine bone","volume":"23","author":"Iversen","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419212974700_CIT0014","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2020110419212974700_CIT0015","doi-asserted-by":"crossref","first-page":"e01822-16","DOI":"10.1128\/AAC.01822-16","article-title":"Rifampin-based combination therapy is active in foreign-body osteomyelitis after prior rifampin monotherapy","volume":"61","author":"Brinkman","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419212974700_CIT0016","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/B978-012775390-4\/50205-0","article-title":"Rat model of bacterial osteomyelitis of the tibia","volume-title":"Handbook of animal models of infection","author":"O\u2019Reilly","year":"1999"},{"key":"2020110419212974700_CIT0017","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1128\/AAC.00740-10","article-title":"Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis","volume":"55","author":"Vergidis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419212974700_CIT0018","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jinf.2014.12.016","article-title":"Comparative activities of vancomycin, tigecycline and rifampin in a rat model of methicillin-resistant Staphylococcus aureus osteomyelitis","volume":"70","author":"Vergidis","year":"2015","journal-title":"J Infect"},{"key":"2020110419212974700_CIT0019","first-page":"691","article-title":"Antimicrobial assays","volume-title":"Laboratory procedures in clinical microbiology","author":"Anhalt","year":"1985"},{"key":"2020110419212974700_CIT0020","article-title":"CLSI standard M07","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018","edition":"11th ed"},{"key":"2020110419212974700_CIT0021","article-title":"CLSI supplement M100","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019","edition":"29th ed."},{"key":"2020110419212974700_CIT0022","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1128\/AAC.42.10.2590","article-title":"Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus","volume":"42","author":"Aubry-Damon","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419212974700_CIT0023","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jclinepi.2014.03.012","article-title":"False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies","volume":"67","author":"Glickman","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2020110419212974700_CIT0024","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1128\/9781555819866.ch8","article-title":"The role of therapeutic drug monitoring in mycobacterial infections.","author":"Peloquin","year":"2017","journal-title":"Tuberculosis and Nontuberculous Mycobacterial Infections, 7th Ed, Washington, DC: ASM Press,"},{"key":"2020110419212974700_CIT0025","author":"Rybak"},{"key":"2020110419212974700_CIT0026","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020110419212974700_CIT0027","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1007\/s11999-015-4300-3","article-title":"Rifamycin derivatives are effective against staphylococcal biofilms in vitro and elutable from PMMA","volume":"473","author":"Sanchez","year":"2015","journal-title":"Clin Orthop Relat Res"},{"key":"2020110419212974700_CIT0028","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/1469-0691.12003","article-title":"Antimicrobial treatment concepts for orthopaedic device-related infection","volume":"18","author":"Sendi","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2020110419212974700_CIT0029","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tube.2010.02.001","article-title":"Rifamycins\u2014obstacles and opportunities","volume":"90","author":"Aristoff","year":"2010","journal-title":"Tuberculosis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa401\/33734463\/jiaa401.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/9\/1498\/33828331\/jiaa401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/9\/1498\/33828331\/jiaa401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T01:11:00Z","timestamp":1604538660000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/222\/9\/1498\/5868461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,7,7]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa401","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,1]]},"published":{"date-parts":[[2020,7,7]]}}}